BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38668070)

  • 21. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
    Tesfaye AA; Philip PA
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series.
    Pinelli D; Micalef A; Merelli B; Trezzi R; Amaduzzi A; Agnesi S; Guizzetti M; Camagni S; Fedele V; Colledan M
    Cancer Treat Res Commun; 2023; 37():100770. PubMed ID: 37837717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
    Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
    J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
    Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
    World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [R1 resection for pancreatic carcinoma].
    Weber GF; Kersting S; Haller F; Grützmann R
    Chirurg; 2017 Sep; 88(9):764-770. PubMed ID: 28653152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.
    Walters DM; Lapar DJ; de Lange EE; Sarti M; Stokes JB; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Oct; 18(10):2764-71. PubMed ID: 21484522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection.
    Cha DE; Yu AT; Khajoueinejad N; Gleeson E; Shaltiel T; Berger Y; Macfie R; Golas BJ; Sarpel U; Labow DM; Hiotis S; Cohen NA
    World J Surg; 2023 Jul; 47(7):1801-1808. PubMed ID: 37014430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The determinant factors of recurrence following resection for ductal pancreatic cancer.
    Barugola G; Falconi M; Bettini R; Boninsegna L; Casarotto A; Salvia R; Bassi C; Pederzoli P
    JOP; 2007 Jan; 8(1 Suppl):132-40. PubMed ID: 17228145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.
    Strobel O; Hartwig W; Hackert T; Hinz U; Berens V; Grenacher L; Bergmann F; Debus J; Jäger D; Büchler M; Werner J
    Ann Surg Oncol; 2013 Mar; 20(3):964-72. PubMed ID: 23233235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surgery of malignant pancreatic tumors].
    Loos M; Friess H; Kleeff J
    Radiologe; 2009 Feb; 49(2):137-43. PubMed ID: 19153706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery.
    Dickinson SM; McIntyre CA; Schilsky JB; Harrington KA; Gerst SR; Flynn JR; Gonen M; Capanu M; Wong W; Lawrence S; Allen PJ; O'Reilly EM; Jarnagin WR; D'Angelica MI; Balachandran VP; Drebin JA; Kingham TP; Simpson AL; Do RK
    Abdom Radiol (NY); 2021 Apr; 46(4):1607-1617. PubMed ID: 32986175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Surgery for pancreatic cancer].
    Welsch T; Büchler MW; Schmidt J
    Z Gastroenterol; 2008 Dec; 46(12):1393-403. PubMed ID: 19053009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.